BMP‐ACVR1 Axis is Critical for Efficacy of PRC2 Inhibitors in B‐Cell Lymphoma

BMP‐ACVR1 Axis is Critical for Efficacy of PRC2 Inhibitors in B‐Cell Lymphoma

Abstract EZH2 is the catalytic subunit of the histone methyltransferase Polycomb Repressive Complex 2 (PRC2), and its somatic activating mutations drive lymphoma, particularly the germinal center B‐cell type. Although PRC2 inhibitors, such as tazemetostat, have demonstrated anti‐lymphoma activity in...

Full description

Bibliographic Details
Main Authors: Dongdong Liu, Zhen Li, Dongxia Tan, Yang An, Liping Chu, Tiancheng Chen, Weijia Li, Ailin Zhou, Ruijie Xiang, Liye Zhang, Yuxiu Qu, Wei Qi
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:Advanced Science
Subjects:
ACVR1
B‐cell lymphoma
biomarker
BMP
cancer therapeutics
PRC2 inhibitors
Online Access:https://doi.org/10.1002/advs.202306499

Internet

https://doi.org/10.1002/advs.202306499

Similar Items